Advanced Search

 

Study ID Status Title Patient Level Data
106640 Completed Evaluate the anti-HBs antibody persistence, in subjects who received GSK Biologicals’ preservative-free or thiomersal-free Engerix™-B or Engerix™-B containing thiomersal, approximately 5 to 6 yrs earlier Study Listed on ClinicalStudyDataRequest.com
106670 Completed Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine to healthy children aged 11 to 21 months.
106672 Completed Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097 Study Listed on ClinicalStudyDataRequest.com
106718 Completed A randomized, double-blind, placebo-controlled, parallel-group, study evaluating the efficacy, safety, and duration of erection of flexible-dose vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and dyslipidemia
106744 Completed Multicentre study to assess persistence of antibodies against hepatitis B and immune response to a hepatitis B challenge dose in healthy children 7 to 9 years old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine Study Listed on ClinicalStudyDataRequest.com
106745 Completed Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 4 to 6 years old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine Study Listed on ClinicalStudyDataRequest.com
106750 Completed Observer-blind monocentric study in adults aged between 18-60 years to evaluate reactogenicity and immunogenicity of 1 and 2 administrations of pandemic monovalent influenza vaccines administered at different antigen doses and adjuvanted or not Study Listed on ClinicalStudyDataRequest.com
106777 Completed Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects
106786 Completed A phase II, observer-blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DssiTgdPa-HBV-IPV/Hib vaccine containing diphtheria toxoid from the Statens Serum Institute (SSI) of Denmark and tetanus toxoid from GSK Biologicals’ Kft [GD], compared to the currently licensed GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa TM) when administered to healthy infants at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
106789 Completed Assess long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children aged 4-5 years (previously primed & boosted in the 1st 2 years of life with DTPa-HBV-IPV/Hib vaccine) Study Listed on ClinicalStudyDataRequest.com
106793 Completed Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine Engerix™-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy
106794 Recruiting Persistence of hepatitis B antibodies, immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of Infanrix™ hexa (SB217744) during infancy
106827 Completed HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Study Listed on ClinicalStudyDataRequest.com
106829 Completed HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents Study Listed on ClinicalStudyDataRequest.com
106837 Completed A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Study Listed on ClinicalStudyDataRequest.com
106839 Completed A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma Study Listed on ClinicalStudyDataRequest.com
106847 Withdrawn A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects with Exercise-Induced Bronchoconstriction
106851 Completed Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics Study Listed on ClinicalStudyDataRequest.com
106853 Completed A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy Study Listed on ClinicalStudyDataRequest.com
106855 Completed A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma
106870 Completed A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma Study Listed on ClinicalStudyDataRequest.com
106915 Completed Eptifibatide versus Abciximab in primary PCI for acute ST elevation myocardial infarction
106962 Completed An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' 11PCV vaccine given as a 2-dose vaccination in adults aged 18-40 years old.
107005 Completed To assess safety, reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age. Study Listed on ClinicalStudyDataRequest.com
107007 Completed To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.